Compugen Stock Performance
CGEN Stock | USD 1.61 0.09 5.92% |
The firm shows a Beta (market volatility) of 2.28, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Compugen will likely underperform. At this point, Compugen has a negative expected return of -0.3%. Please make sure to confirm Compugen's kurtosis, and the relationship between the maximum drawdown and day median price , to decide if Compugen performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Compugen has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
1 | Compugen Upgraded to Strong Buy What Does It Mean for the Stock | 09/11/2024 |
2 | Compugen to Present New Clinical Data at SITC 2024 - StockTitan | 10/07/2024 |
3 | Compugen Strengthens Defence Security Industry with Strategic Acquisition of SynerSolutions | 11/04/2024 |
4 | Compugen shareholder returns have been stellar, earning 204 percent in 1 year | 11/08/2024 |
5 | Compugen earnings beat by 0.11, revenue topped estimates | 11/12/2024 |
6 | Compugen Ltd. Q3 2024 Earnings Call Transcript | 11/13/2024 |
7 | Compugen Releases Earnings Results | 11/14/2024 |
8 | Compugen Stock Dips Amidst Biotech Sector Movements | 11/22/2024 |
Begin Period Cash Flow | 11.4 M |
Compugen |
Compugen Relative Risk vs. Return Landscape
If you would invest 203.00 in Compugen on August 29, 2024 and sell it today you would lose (42.00) from holding Compugen or give up 20.69% of portfolio value over 90 days. Compugen is currently does not generate positive expected returns and assumes 3.5821% risk (volatility on return distribution) over the 90 days horizon. In different words, 31% of stocks are less volatile than Compugen, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
Risk |
Compugen Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Compugen's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Compugen, and traders can use it to determine the average amount a Compugen's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0832
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns | CGEN |
Estimated Market Risk
3.58 actual daily | 31 69% of assets are more volatile |
Expected Return
-0.3 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
-0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Compugen is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Compugen by adding Compugen to a well-diversified portfolio.
Compugen Fundamentals Growth
Compugen Stock prices reflect investors' perceptions of the future prospects and financial health of Compugen, and Compugen fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Compugen Stock performance.
Return On Equity | -0.16 | ||||
Return On Asset | -0.0304 | ||||
Profit Margin | (0.22) % | ||||
Operating Margin | (0.51) % | ||||
Current Valuation | 17.1 M | ||||
Shares Outstanding | 89.54 M | ||||
Price To Earning | (4.86) X | ||||
Price To Book | 2.25 X | ||||
Price To Sales | 3.19 X | ||||
Revenue | 33.46 M | ||||
Gross Profit | 6.53 M | ||||
EBITDA | (12.52 M) | ||||
Net Income | (18.75 M) | ||||
Cash And Equivalents | 88.21 M | ||||
Cash Per Share | 1.02 X | ||||
Total Debt | 1.35 M | ||||
Debt To Equity | 0.02 % | ||||
Current Ratio | 6.16 X | ||||
Book Value Per Share | 0.73 X | ||||
Cash Flow From Operations | (35.89 M) | ||||
Earnings Per Share | 0.03 X | ||||
Market Capitalization | 136.1 M | ||||
Total Asset | 121.33 M | ||||
Retained Earnings | (474.53 M) | ||||
Working Capital | 88.31 M | ||||
Current Asset | 53.09 M | ||||
Current Liabilities | 8.38 M | ||||
About Compugen Performance
By examining Compugen's fundamental ratios, stakeholders can obtain critical insights into Compugen's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Compugen is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Last Reported | Projected for Next Year | ||
Days Of Inventory On Hand | -31.3 K | -32.8 K | |
Return On Tangible Assets | (0.15) | (0.16) | |
Return On Capital Employed | (0.14) | (0.14) | |
Return On Assets | (0.15) | (0.16) | |
Return On Equity | (0.29) | (0.30) |
Things to note about Compugen performance evaluation
Checking the ongoing alerts about Compugen for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Compugen help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Compugen generated a negative expected return over the last 90 days | |
Compugen may become a speculative penny stock | |
Compugen has high historical volatility and very poor performance | |
The company reported the previous year's revenue of 33.46 M. Net Loss for the year was (18.75 M) with profit before overhead, payroll, taxes, and interest of 6.53 M. | |
Compugen currently holds about 88.21 M in cash with (35.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.02. | |
Latest headline from gurufocus.com: Compugen Stock Dips Amidst Biotech Sector Movements |
- Analyzing Compugen's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Compugen's stock is overvalued or undervalued compared to its peers.
- Examining Compugen's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Compugen's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Compugen's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Compugen's stock. These opinions can provide insight into Compugen's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Compugen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Compugen Stock, please use our How to Invest in Compugen guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Compugen. If investors know Compugen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Compugen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.03 | Revenue Per Share 0.48 | Quarterly Revenue Growth 3.461 | Return On Assets (0.03) | Return On Equity (0.16) |
The market value of Compugen is measured differently than its book value, which is the value of Compugen that is recorded on the company's balance sheet. Investors also form their own opinion of Compugen's value that differs from its market value or its book value, called intrinsic value, which is Compugen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Compugen's market value can be influenced by many factors that don't directly affect Compugen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Compugen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Compugen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Compugen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.